menu
    • menu
    [{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Sanofi Ventures","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"EP547","moa":"MRGPRX4","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Sanofi Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Sanofi Ventures"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"EP547","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"NEA","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2022","type":"Series C Financing","leadProduct":"EP547","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.12,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ NEA","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ NEA"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"EP262","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"EP262","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"EP262","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"EP262","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"EP262","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"EP262","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0.75,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.75,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Incyte Corporation"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"EP262","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"EP262","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0.75,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.75,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Incyte Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals by Escient Pharmaceuticals

    Menu

    Escient Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP262

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Incyte Corporation

                            Deal Size : $750.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Incyte Completes Acquisition of Escient Pharmaceuticals

                            Details : Incyte will gain access to Escient's pipeline, which includes EP262, a potent, highly selective once-daily small molecule antagonist of MRGPRX2, currently undergoing evaluation for atopic dermatitis.

                            Brand Name : EP262

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 30, 2024

                            Lead Product(s) : EP262

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Incyte Corporation

                            Deal Size : $750.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP262

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Incyte Corporation

                            Deal Size : $750.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Incyte Acquires Escient Pharmaceuticals and Its Pipeline of Oral MRGPR Antagonists

                            Details : Incyte gains access to Escient's pipeline, including EP262, a selective small molecule antagonist of MRGPRX2 for atopic dermatitis.

                            Brand Name : EP262

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 23, 2024

                            Lead Product(s) : EP262

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Incyte Corporation

                            Deal Size : $750.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP262

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Anta...

                            Details : EP262 is a potent, highly selective once-daily small molecule antagonist of MRGPRX2, a receptor expressed on mast cells that is activated by numerous ligands, being developed for atopic dermatitis.

                            Brand Name : EP262

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 28, 2023

                            Lead Product(s) : EP262

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP262

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Anta...

                            Details : EP262 is a potent, highly selective once-daily small molecule antagonist of MRGPRX2, a receptor expressed on mast cells that is activated by numerous ligands, including many peptides released from sensory neurons as well as other cell types.

                            Brand Name : EP262

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 12, 2023

                            Lead Product(s) : EP262

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP262

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Anta...

                            Details : EP262 is a potent, highly selective small molecule antagonist of MRGPRX2, a receptor mediating non-IgE driven mast cell degranulation. By blocking activation of MRGPRX2 and degranulation of mast cells, it effectively treat Chronic Inducible Urticaria.

                            Brand Name : EP262

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 25, 2023

                            Lead Product(s) : EP262

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP262

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP262, a First-In-Class Oral Mrgprx2 ...

                            Details : EP262 is a potent, highly selective small molecule antagonist of MRGPRX2, a receptor mediating non-IgE driven mast cell degranulation. By blocking activation of MRGPRX2 and degranulation of mast cells, it effectively treat a broad range of mast cell medi...

                            Brand Name : EP262

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 20, 2023

                            Lead Product(s) : EP262

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP262

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Escient Pharmaceuticals Announces IND Clearance by FDA to Start Phase 1 Study of EP262, a First-in-Class Oral ...

                            Details : EP262 is a potent, highly selective small molecule antagonist of MRGPRX2, a receptor mediating non-IgE driven mast cell degranulation. By blocking activation of MRGPRX2 and degranulation of mast cells, it effectively treat a broad range of mast cell medi...

                            Brand Name : EP262

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 30, 2023

                            Lead Product(s) : EP262

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP262

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Development of EP262 ...

                            Details : EP262, a potent, highly selective antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), represents a novel, targeted approach to the treatment of mast cell-mediated disorders.

                            Brand Name : EP262

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 07, 2022

                            Lead Product(s) : EP262

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP547

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : NEA

                            Deal Size : $120.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Escient Pharmaceuticals Announces $120 Million Series C Financing

                            Details : Proceeds from the financing will be used to advance the company’s pipeline of two first-in-class product candidates in several indications.

                            Brand Name : EP547

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 28, 2022

                            Lead Product(s) : EP547

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : NEA

                            Deal Size : $120.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Escient Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP547

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Escient Pharmaceuticals Initiates Phase 2 PACIFIC Study Evaluating EP547, An Oral MRGPRX4 Antagonist, in Subje...

                            Details : EP547 is highly selective antagonist of MRGPRX4, cell surface receptor expressed on sensory neurons that is activated by bile acids, bilirubin and other heme metabolites and thought key mediator of often intense itch experienced by patients with cholesta...

                            Brand Name : EP547

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 17, 2022

                            Lead Product(s) : EP547

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth